TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S.

In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...

TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised ...

Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...

NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Izervay to treat geographic atrophy. Izervay demonstrated statistically significant reduction ...

Over 2 years, only a slight increased incidence of choroidal neovascularization was observed for IZERVAY pooled vs. sham; in year 2, incidence of CNV was similar for IZERVAY EOM vs. sham "GA is a ...

"Geographic atrophy is a progressive disease that can lead to irreversible vision loss and early treatment can have a significant impact on patients' lives. Receiving a permanent J-code in the U.S.